Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HIMS NYSE:NVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$51.30-7.6%$53.79$13.47▼$72.98$12.43B2.0836.46 million shs45.99 million shsNVONovo Nordisk A/S$45.31-4.0%$67.96$45.05▼$139.74$210.84B0.6320.61 million shs37.33 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health-7.51%-21.71%+6.11%-0.26%+204.06%NVONovo Nordisk A/S-4.00%-9.45%-34.63%-30.06%-65.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHIMSHims & Hers Health2.5731 of 5 stars2.03.00.00.02.43.31.9NVONovo Nordisk A/S4.1819 of 5 stars3.05.02.50.02.90.03.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHIMSHims & Hers Health 1.92Reduce$39.83-22.34% DownsideNVONovo Nordisk A/S 2.00Hold$93.67106.72% UpsideCurrent Analyst Ratings BreakdownLatest NVO and HIMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold8/5/2025NVONovo Nordisk A/SUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/31/2025NVONovo Nordisk A/SHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/31/2025NVONovo Nordisk A/SHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$57.007/30/2025NVONovo Nordisk A/SBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight7/17/2025HIMSHims & Hers HealthTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$45.00 ➝ $48.006/24/2025HIMSHims & Hers HealthTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$45.006/23/2025HIMSHims & Hers HealthCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell6/23/2025HIMSHims & Hers HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$30.006/23/2025HIMSHims & Hers HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderperform ➝ Underperform6/23/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHIMSHims & Hers Health$1.48B7.78$0.33 per share157.65$2.51 per share20.44NVONovo Nordisk A/S$42.12B4.80$3.74 per share12.10$4.66 per share9.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHIMSHims & Hers Health$126.04M$0.6964.1298.642.069.63%26.26%13.06%N/ANVONovo Nordisk A/S$14.64B$3.3813.419.721.4334.52%80.94%24.23%N/ALatest NVO and HIMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025 NVONovo Nordisk A/S$0.89$0.97+$0.08$0.91$77.51 billionN/A8/4/2025Q2 2025HIMSHims & Hers Health$0.18$0.17-$0.01$0.17$550.06 million$544.83 million5/7/2025Q1 2025NVONovo Nordisk A/S$0.92$0.92N/A$0.92N/A$11.87 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHIMSHims & Hers HealthN/AN/AN/AN/AN/ANVONovo Nordisk A/S$1.643.62%N/A48.52%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHIMSHims & Hers HealthN/A1.591.32NVONovo Nordisk A/S0.700.740.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHIMSHims & Hers Health63.52%NVONovo Nordisk A/S11.54%Insider OwnershipCompanyInsider OwnershipHIMSHims & Hers Health13.71%NVONovo Nordisk A/S0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHIMSHims & Hers Health1,637223.83 million193.15 millionOptionableNVONovo Nordisk A/S77,3494.47 billion4.46 billionOptionableNVO and HIMS HeadlinesRecent News About These CompaniesOzempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation1 hour ago | aol.comAQ2 2025 Novo Nordisk A/S Earnings Call Transcript3 hours ago | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo ...August 6 at 7:04 PM | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVOAugust 6 at 6:40 PM | prnewswire.comNovo Nordisk A/S (NYSE:NVO) Shares Down 3.5% - Should You Sell?August 6 at 3:21 PM | marketbeat.comBest Growth Stocks To Watch Today - August 6thAugust 6 at 2:38 PM | marketbeat.comLaw Offices of Howard G. Smith Encourages Novo Nordisk A/S (NVO) Investors To Inquire About ...August 6 at 2:13 PM | gurufocus.comNovo Nordisk A/S (NYSE:NVO) Reaches New 52-Week Low - Should You Sell?August 6 at 1:50 PM | marketbeat.comNovo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US HurdlesAugust 6 at 1:21 PM | zacks.comLaw Offices of Howard G. Smith Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class ActionAugust 6 at 1:15 PM | businesswire.comLaw Offices of Frank R. Cruz Encourages Novo Nordisk A/S (NVO) Investors To Inquire About ...August 6 at 1:08 PM | gurufocus.comLaw Offices of Frank R. Cruz Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class ActionAugust 6 at 12:07 PM | businesswire.comNovo Nordisk A/S (NVO) Q2 2025 Earnings Call TranscriptAugust 6 at 12:02 PM | seekingalpha.comNovo Nordisk A/S 2025 Q2 - Results - Earnings Call PresentationAugust 6 at 11:10 AM | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk ...August 6 at 11:05 AM | gurufocus.comInvestors Purchase High Volume of Put Options on Novo Nordisk A/S (NYSE:NVO)August 6 at 11:05 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVOAugust 6 at 10:00 AM | prnewswire.comNovo Nordisk Slumps As It Cautions 'Unsafe And Unlawful' Knockoffs Will Pressure WegovyAugust 6 at 9:16 AM | investors.comNovo Nordisk: Is there life after slow death for slimmed down drug maker?August 6 at 7:47 AM | proactiveinvestors.co.ukRoberts Glore & Co. Inc. IL Raises Holdings in Novo Nordisk A/S (NYSE:NVO)August 6 at 7:10 AM | marketbeat.comNovo Nordisk A/S (NYSE:NVO) Shares Bought by Legacy Capital Group California Inc.August 6 at 6:36 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Novo Nordisk Stock Sinks—But Is a Bottom Finally In?By Chris Markoch | August 5, 2025View Novo Nordisk Stock Sinks—But Is a Bottom Finally In?Will Hims & Hers Fall Along With Novo Nordisk?By Gabriel Osorio-Mazilli | August 1, 2025View Will Hims & Hers Fall Along With Novo Nordisk?Diagnosis: Hims & Hers' August Price Dip Is an Opportunity to BuyBy Thomas Hughes | August 6, 2025View Diagnosis: Hims & Hers' August Price Dip Is an Opportunity to BuyNVO and HIMS Company DescriptionsHims & Hers Health NYSE:HIMS$51.30 -4.23 (-7.61%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$51.51 +0.21 (+0.42%) As of 08/6/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Novo Nordisk A/S NYSE:NVO$45.31 -1.91 (-4.04%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$45.54 +0.23 (+0.51%) As of 08/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
